The Filing Desk

PROCEPT BioRobotics

PRCT · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

PRCT · Last close · November 13, 2026
$23.80
Value PROCEPT BioRobotics yourself

PROCEPT BioRobotics' revenue rose 37.2% to $308 million in fiscal 2025. Its operating margin was −33.7%, up from −43.0% a year earlier. Free cash flow was −$58 million. The diluted share count rose 6.6%.

PROCEPT BioRobotics Corporation Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001588978-26-000009 Updated
Revenue
$308M
37.2%
Operating margin
−33.7%
9.3 pts
Net income
−$96M
 
Free cash flow
−$58M
 
Return on capital
−65.4%
13.0 pts
Market cap
$1.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What PROCEPT BioRobotics does

PROCEPT BioRobotics makes surgical robots for urology, the care of the urinary system. Its first focus is benign prostatic hyperplasia, or BPH, a non-cancerous enlargement of the prostate that can block the flow of urine. Hospitals buy its robotic systems, which use a single-use handpiece to carry out Aquablation therapy. The therapy combines imaging, treatment planning, a robot and a heat-free waterjet to remove prostate tissue.

The company earns money from selling its robotic systems, the AquaBeam and the HYDROS, and from the disposable handpieces used in each procedure. Its revenue depends mainly on these two. It sells through its own team and, in some markets, through third-party distributors. It says it competes with other surgical treatments for BPH, with drug therapy and with larger companies.

The company began developing the AquaBeam system in 2009. It says its clinical evidence includes clinical studies and many peer-reviewed publications. It has a loan agreement that sets operating and financial requirements.

Its biggest risks, as it describes them

  • A history of net losses, with more losses expected and no certainty of lasting profitability.
  • Dependence on sales of its robotic systems and the single-use handpieces used with them.
  • Hospitals, surgeons and patients may not accept its products widely enough.
  • Insurers may not cover or pay for its procedures at adequate levels.
  • Reliance on third-party and single-source suppliers and contract manufacturers.
From PROCEPT BioRobotics's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

PROCEPT BioRobotics lost money in fiscal 2025: a net loss of $96 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments304222257334286
Debt incl. finance leases5051515252
Net debt (negative means net cash)−254−171−206−282−235
Net debt to EBITDA—————
Debt to equity0.2x0.3x0.2x0.1x0.1x
Interest coverage−9.3x−15.6x−27.3x−23.1x−29.0x
Current ratio20.1x7.7x7.6x9.1x6.8x
Quick ratio19.3x6.9x6.8x8.0x5.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project PROCEPT BioRobotics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of PROCEPT BioRobotics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 95 of 95 of 9
Rule of 40−16.3%18.7%18.3%
Altman Z''1.843.922.18
Accruals ratio0.6%1.7%−8.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score3 of 95 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put PROCEPT BioRobotics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PROCEPT BioRoboticsFY2537.2%−33.7%−18.9%−65.4%—5
AngiodynamicsFY269.5%−12.5%0.2%−24.6%—4Compare
Tactile Systems TechnologyFY2512.5%8.9%12.3%12.6%−2.3x8Compare
LeMaitre VascularFY2513.5%27.2%29.8%25.5%−2.4x5Compare
STAAR SurgicalFY25−23.7%−38.3%−16.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue83475136224308
Revenue growth—346.7%117.6%81.5%64.8%37.2%
Gross profit−1163771137196
Research and development161929486271
Operating income−48−54−81−109−97−104
Net income−53−60−87−106−91−96
Diluted EPS (US$)−14.47−3.63−1.96−2.24−1.75−1.72
Diluted shares (millions)41644475256
Cash flow
Cash from operations−48−57−80−108−99−49
Capital expenditure0132549
Free cash flow−49−58−83−133−104−58
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation2410193248
Balance sheet at fiscal year end
Cash and short-term investments100304222257334286
Debt incl. finance leases495051515252
Total assets126337309405534508
Total liabilities6570112124132142
Shareholders' equity−183267197281402366
Margins and ratios
Gross margin−16.3%46.0%49.4%52.2%61.1%63.7%
Operating margin−619.4%−157.1%−107.6%−80.2%−43.0%−33.7%
Net margin−687.0%−173.6%−116.2%−77.8%−40.7%−31.0%
Free cash flow margin−629.5%−168.0%−110.7%−97.8%−46.2%−18.9%
Rule of 40 (growth + FCF margin)—178.7%6.9%−16.3%18.7%18.3%
Return on capital———−170.3%−78.3%−65.4%
Return on equity—−142.2%−37.5%−44.3%−26.8%−24.9%
Return on assets—−25.9%−27.0%−29.7%−19.5%−18.3%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: PROCEPT BioRobotics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with PROCEPT BioRobotics.